There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research Report), Elanco Animal Health (ELAN – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
NewAmsterdam Pharma Company (NAMS)
In a report released today, George Farmer from Scotiabank maintained a Buy rating on NewAmsterdam Pharma Company, with a price target of $35.00. The company’s shares closed last Thursday at $20.05.
According to TipRanks.com, Farmer is a 4-star analyst with an average return of
NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $37.00, an 84.5% upside from current levels. In a report issued on May 8, RBC Capital also maintained a Buy rating on the stock with a $31.00 price target.
See the top stocks recommended by analysts >>
Elanco Animal Health (ELAN)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Elanco Animal Health, with a price target of $22.00. The company’s shares closed last Thursday at $16.98, close to its 52-week high of $17.43.
According to TipRanks.com, Block is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elanco Animal Health with a $19.00 average price target, representing a 12.2% upside. In a report issued on May 9, Barclays also maintained a Buy rating on the stock with a $23.00 price target.
Disc Medicine (IRON)
In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Disc Medicine, with a price target of $72.00. The company’s shares closed last Thursday at $31.92, close to its 52-week low of $25.60.
According to TipRanks.com, Burnett has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $57.33, which is an 80.3% upside from current levels. In a report issued on May 9, BMO Capital also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NAMS:
- NewAmsterdam Pharma initiated with a Buy at TD Cowen
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
- NewAmsterdam Pharma reports Q1 EPS ($1.06), consensus (53c)
- Is NAMS a Buy, Before Earnings?
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
